Europe Collaborates on Generic Drugs
The European Medicines Agency plans on sharing generic-drug assessment reports with regulators outside the European Union.
As part of the International Generic Drug Regulators Pilot (IGDRP), the European Medicines Agency (EMA) is providing the agency’s assessments of applications for generic medicines in real time with collaborating regulatory agencies outside the European Union (EU). EMA is sharing the assessments as part of an information-sharing initiative to ensure timely authorization and availability of generic drugs.
IGDRP was started in July 2014 using the EU-decentralized procedure as a model, and it is now extended to the centralized procedure. According to the EMA, the aim of the pilot is to “both save global assessment resources and to facilitate and strengthen the scientific assessment process for medicines. It is expected that this sharing of assessments will allow authorization of generic products in concerned countries in a coordinated and resource effective way.”
Source: European Medicines Agency
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
